

Case Report

The Partial Duplication of the 5' Segment of *KMT2A* Revealed *KMT2A-MLLT10* Rearrangement in a Boy with Acute Myeloid Leukemia

Hiroko Fukushima,¹ Toru Nanmoku,² Sho Hosaka,³ Yuni Yamaki,³ Nobutaka Kiyokawa,⁴ Takashi Fukushima,¹ and Ryo Sumazaki¹

¹Department of Child Health, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

²Department of Clinical Laboratory, University of Tsukuba Hospital, Ibaraki, Japan

³Department of Pediatrics, University of Tsukuba Hospital, Ibaraki, Japan

⁴Department of Pediatric Haematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan

Correspondence should be addressed to Takashi Fukushima; tksfksm@md.tsukuba.ac.jp

Received 10 April 2017; Revised 3 July 2017; Accepted 23 November 2017; Published 28 December 2017

Academic Editor: Anselm Chi-wai Lee

Copyright © 2017 Hiroko Fukushima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The duplication of 5' segment of *KMT2A* is a rare molecular event in childhood leukemia, and the influence on prognosis is unknown. Here, we report on a boy who developed acute monocytic leukemia. Fluorescence in situ hybridization revealed the duplication of the 5' segment with 2 normal alleles at *KMT2A* which was eventually found to be fused with *MLLT10*. Chemotherapy promptly induced the first complete remission in the patient at our facility, and the patient remained in first complete remission with negative minimal residual disease at 3.5 years from diagnosis. Our case is similar to two previously reported patients who had partial duplication of the 5' segment of *KMT2A* with a *KMT2A-MLLT10* rearrangement. Further studies and experience with this cryptic translocation may shed more light on the management of acute myeloid leukemia.

1. Introduction

The histone-lysine *N*-methyltransferase 2A enzyme (*MLL1*), encoded by the *KMT2A* gene, is an upregulator of global, hematopoietic gene transcription, and translocation rearrangement within *KMT2A* causes variable risk stratification in acute leukemia based on the final genetic outcome.

Patients with *MLL* rearrangement other than t(9;11) and t(11;19) have an inferior outcome [1], and there are additional aberrations in *KMT2A* rearrangement, such as fusion with preferential partner gene *MLLT10*, that also carry prognostic significance [2].

One of these aberrations is the duplication/amplification of the 5' segment of *KMT2A*, which is a very rare molecular event, and the influence of this on patient prognosis is unknown. However, in general, *KMT2A* amplification as an

acquired genetic aberration has been reported to result in a poor prognosis [3]. With this deleterious effect of *KMT2A* overexpression in acute leukemia in mind, it is possible that even partial amplification could affect the patient's prognosis. In the literature, only 2 cases have been reported: one pediatric case of AML-M5b(FAB: French-American-British Classification) with the duplicated 5' segment of *KMT2A* relapsed 16 months after diagnosis during maintenance therapy and was later salvaged by allogeneic transplantation [4] and an adult case of AML-M5a(FAB) with an amplified 5' part of 11q23.3 where *KMT2A* was located eventually needed transplantation [5]. In both literature cases, this partial duplication was paired with *KMT2A-MLLT10* rearrangement.

Although preferential fusion with *MLLT10* has been well documented, the isolated prognostic importance of the partial amplification of *KMT2A* remains unknown. Here, we




FIGURE 1: FISH and RT-PCR of the *KMT2A* rearrangement. (a) FISH of the *KMT2A* break apart signal: the green signal shows the 5' segment, and the red signal shows the 3' segment of *KMT2A*. FISH revealed 2 normal signals (arrowhead) and 1 additional 5' segment (arrow). Positive cells with duplication of the 5' segment of *KMT2* were observed in 686 out of 1000 cells. (b) The characterization of *KMT2A-MLLT10* fusion transcript at bone marrow by RT-PCR. 1: ladder; 2: normal control; 3: at diagnosis; 4: after induction therapy 1; 5: after induction therapy 2; 6: after intensification 1; 7: after intensification 2; 8 and 9: after intensification 3.

TABLE 1: All sequencing data for breakpoint.

catcaaccaattaacactgtcactagaacaaggcaccagggaacctccagtaaagaaggacgtcgcgagggcggtgtgggcaggtgccggctgccaggtgcctgaggactgtggtttgtacta
attgcttagataagccaagtttggtggcgcaatataaagaagcagtgctgcaagatgagaaaatgcagaatctacaatggatgcctccaagcctacctgcagaagcaagctaaag(breakpoint)
 aggtattataacagcaatgatgtagcagatcgtttccaatgtagtatctggctcgggatctagtactcctgtctccagctctcactacctcagcagcttctgggcattgcaacaagtaggagcgcctctc
 cctcagctgtgtcatctgcagcccctgctgtgtcacaactcaggcaatactctatctggatcttctcagtcaggcaccatctcatatgtaggcaatagatcaaatcatcaatggcagctcttatagctcag
 tctgaaacaatcaaacag

Underlined sequencing was from *KMT2A*, and nonunderlined sequencing was from *MLLT10*.

present the case of a pediatric male patient with AML who was successfully treated by multiagent chemotherapy alone. The 5' duplication of *KMT2A* was identified by fluorescence in situ hybridization (FISH) before treatment, but fusion to *MLLT10* was discovered by RNA sequencing after completion of the treatment even though reverse transcription-PCR at the diagnosis did not detect any fusion partners.

2. Case Description

A 6-year-old boy was admitted with complaints of low-grade fever, multiple joint pain, skin rash, and neutropenia. A complete blood count was conducted; leukocytes were $1.6 \times 10^9/L$, hemoglobin was 9.1 g/dl, and platelet count was $222 \times 10^9/L$. The bone marrow was replaced by 90% monoblasts. Flow cytometry was conducted on the leukemic cells. HLA-DR, CD58, CD99, CD56, CD38, cy-MPO, CD11b, CD13, CD33, CD65, CD64, CD117, CD36, CD61, CD4, and 7.1 were positive, and CD14, CD15, CD19, CD10, CD20, CD3, and CD7 were negative. He was diagnosed with AML (FAB M5a). FISH analysis using a *KMT2A* locus-specific dual-color DNA probe (Vysis LSI MLL Dual Color, Break Apart Rearrangement Probe, Abbott Laboratories, IL, USA) was used to characterize the partial 5' duplication and 2 other normal *KMT2A* alleles (Figure 1). Cell culture for chromosomal analysis failed. The search for *KMT2A-MLLT10* fusion was performed according to a publication previously reported [6]. Reverse transcription-polymerase chain reaction of major fusion partners to *KMT2A* (including *MLLT10*) was conducted and none were amplified. The primer for *KMT2A* was designed in exon 8.

Final diagnosis, in this case, was AML with 11q23/*KMT2A* abnormalities (FAB M5a) without any confirmation of partner genes. As he presented no abnormalities such as t(8;21), inv(16), -7, 5q-, t(16;21) (p11;q22), Ph1, and *FLT3-ITD*, he underwent multimodal chemotherapy for the intermediate risk group according to JPLSG AML05, which consists of induction 1 (ECM: etoposide 150 mg/m²/day on days 1–5, cytarabine 200 mg/m²/day on days 6–12, mitoxantrone 5 mg/m²/day on days 6–10, and intrathecal chemotherapy on day 6), induction 2 (HCEI: cytarabine 3 g/m² every 12 hours on days 1–3, etoposide 100 mg/m²/day on days 1–5, idarubicin 10 mg/m²/day on day 1, and intrathecal chemotherapy on day 1), and 3 intensification therapy (HCM: cytarabine 2 g/m² every 12 hours on days 1–5, mitoxantrone 5 mg/m²/day on days 1–3, and intrathecal chemotherapy on day 1; HCEI; and HCM) [7]. The chemotherapy promptly induced a first complete remission in the patient which has persisted 3.5 years from diagnosis without hematopoietic stem cell transplantation.

RNA sequencing on NextSeq500 (Illumina, Inc., CA, USA) was then used to screen for fusion partners, revealing a *KMT2A-MLLT10* rearrangement. The RNA analysis was conducted as follows: RNA was purified from the patient's bone marrow at diagnosis using ISOGEN (Nippon Gene Co., Ltd., Tokyo, Japan) according to the manufacturer's instructions. A sequencing library was then generated from 500 ng of total RNA using a TruSeq Stranded mRNA Library Prep Kit v2 (Illumina) according to the manufacturer's instructions. Next, sequencing was conducted at i-Laboratory LLP (Ibaraki, Japan). Obtained reads were aligned

toward human genome assembly hg19, and fusion gene analysis was conducted with CLC Genomics Workbench Ver. 7.5.1 software (Qiagen, Venlo, Netherlands). Four sequencing tags supporting *KMT2A-MLLT10* rearrangement were obtained, which were then confirmed by Sanger sequencing. All sequencing data are shown in Table 1. Designed primers were 5'-TCAATTGCTGGCTCAGAAGA-3' (*KMT2A* exon 5) and 5'-CTGAGCTATAAGAGCTGCCATT-3' (*MLLT10* exon 16). The *KMT2A* breakpoint was located on intron 6, which was the upstream region of the sequencing primer for screening at diagnosis, and the *MLLT10* breakpoint was located on exon 14. Minimal residual disease (MRD) by reverse transcription-polymerase chain reaction (RT-PCR) was assessed from diagnosis as shown in Figure 1. Although MRD was positive at diagnosis, it changed to negative after induction therapy 1.

3. Discussion

Pediatric acute myeloid leukemia is classified by chromosomal and/or genetic abnormalities according to the World Health Organization Classification published in 2008. Chimeric genes including *KMT2A* rearrangements are used to predict disease outcome. *KMT2A* rearrangements are seen in about 20% of pediatric AML and are associated with poor outcome, while the disease outcome depends on its partner gene [1]. *KMT2A* has many partner genes, and each chimeric gene has a different prognosis.

It is difficult to quantify the effect of the partial duplication/amplification of *KMT2A* as the two patients previously reported had the same rearrangement of *KMT2A-MLLT10* with different treatment outcomes. A single abnormality within amplification of *KMT2A* is reported to have a gain-of-function effect for leukemogenesis [3]; however, the exact role of this "partial" duplication of *KMT2A* in acute leukemia is still unclear.

It is interesting to note that both previously reported and the current cases have the same rearrangement along with this partial duplication/amplification and diagnosis of FAB M5. Hence, we hypothesize that the leukemic cells that partially duplicate *KMT2A* tend to undergo *KMT2A-MLLT10* fusion and may act more similarly to *KMT2A-MLLT10* rearrangements caused by the insertion of *KMT2A* in chromosome 10p or an unbalanced translocation. This points to different causes producing the same prognostic effect. Similar rearrangement and the duplication of the 5' segment of *KMT2A* might result in cell culture difficulties in other cases. Therefore, we can recommend using FISH assays to detect partial *KMT2A* duplication, and RNA sequencing may be useful to specify the fusion partner in such cases.

4. Conclusion

Partial duplication of the 5' segment of *KMT2A* can be easily detected by FISH, but the crucial details of the *KMT2A-MLLT10* rearrangement may remain hidden from standard PCR testing, which might result in poor prognosis.

Ethical Approval

This study was approved by the ethics committee of the University of Tsukuba Hospital (H23-128) following the Ethical Guidelines for Medical and Health Research Involving Human Subjects of the Ministry of Health, Labor and Welfare of Japan and the Declaration of Helsinki.

Consent

Written informed consent was obtained from the patient's parents.

Conflicts of Interest

The authors have no conflicts of interest to declare with regard to this work.

Acknowledgments

This work was partially supported by grants from the National Center for Child Health and Development, Tokyo, Japan (26-20). The authors would like to thank Dr. Masafumi Muratani for supporting RNA sequencing, and Mr. Charles N. Jones for scientific writing assistance. Dr. Bryan J. Mathis of the University of Tsukuba Medical English Communications Center also provided critical scientific writing assistance.

References

- [1] C. von Neuhoff, D. Reinhardt, A. Sander et al., "Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98," *Journal of Clinical Oncology*, vol. 28, no. 16, pp. 2682–2689, 2010.
- [2] E. A. Coenen, S. C. Raimondi, J. Harbott et al., "Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study," *Blood*, vol. 117, no. 26, pp. 7102–7111, 2011.
- [3] B. Poppe, J. Vandesompele, C. Schoch et al., "Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies," *Blood*, vol. 103, no. 1, pp. 229–235, 2004.
- [4] M. Jarosova, S. Takacova, M. Holzerova et al., "Cryptic MLL-AF10 fusion caused by insertion of duplicated 5' part of MLL into 10p12 in acute leukemia: a case report," *Cancer Genetics and Cytogenetics*, vol. 162, no. 2, pp. 179–182, 2005.
- [5] I. Sarova, J. Brezinova, Z. Zemanova et al., "Cytogenetic manifestation of chromosome 11 duplication/amplification in acute myeloid leukemia," *Cancer Genetics and Cytogenetics*, vol. 199, no. 2, pp. 121–127, 2010.
- [6] L. Gore, J. Ess, M. A. Bitter et al., "Protean clinical manifestations in children with leukemias containing MLL-AF10 fusion," *Leukemia*, vol. 14, no. 12, pp. 2070–2075, 2000.
- [7] D. Tomizawa, A. Tawa, T. Watanabe et al., "Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children," *Leukemia*, vol. 27, no. 12, pp. 2413–2416, 2013.